390 related articles for article (PubMed ID: 29436696)
1. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
Benedicto A; Romayor I; Arteta B
Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
[TBL] [Abstract][Full Text] [Related]
2. CXCR4/TGF-β1 mediated hepatic stellate cells differentiation into carcinoma-associated fibroblasts and promoted liver metastasis of colon cancer.
Tan HX; Gong WZ; Zhou K; Xiao ZG; Hou FT; Huang T; Zhang L; Dong HY; Zhang WL; Liu Y; Huang ZC
Cancer Biol Ther; 2020; 21(3):258-268. PubMed ID: 31825725
[No Abstract] [Full Text] [Related]
3. CXCR4/TGF-β1 mediated self-differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and promoted colorectal carcinoma development.
Tan HX; Xiao ZG; Huang T; Fang ZX; Liu Y; Huang ZC
Cancer Biol Ther; 2020; 21(3):248-257. PubMed ID: 31818187
[No Abstract] [Full Text] [Related]
4. CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3.
Feng W; Huang W; Chen J; Qiao C; Liu D; Ji X; Xie M; Zhang T; Wang Y; Sun M; Tian D; Fan D; Nie Y; Wu K; Xia L
Theranostics; 2021; 11(6):2612-2633. PubMed ID: 33456563
[No Abstract] [Full Text] [Related]
5. Exosome-encapsulated miRNAs contribute to CXCL12/CXCR4-induced liver metastasis of colorectal cancer by enhancing M2 polarization of macrophages.
Wang D; Wang X; Si M; Yang J; Sun S; Wu H; Cui S; Qu X; Yu X
Cancer Lett; 2020 Apr; 474():36-52. PubMed ID: 31931030
[TBL] [Abstract][Full Text] [Related]
6. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD
Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis.
Martinez-Ordoñez A; Seoane S; Cabezas P; Eiro N; Sendon-Lago J; Macia M; Garcia-Caballero T; Gonzalez LO; Sanchez L; Vizoso F; Perez-Fernandez R
Oncogene; 2018 Mar; 37(11):1430-1444. PubMed ID: 29321662
[TBL] [Abstract][Full Text] [Related]
8. Modulating the interaction of CXCR4 and CXCL12 by low-molecular-weight heparin inhibits hepatic metastasis of colon cancer.
Ma L; Qiao H; He C; Yang Q; Cheung CH; Kanwar JR; Sun X
Invest New Drugs; 2012 Apr; 30(2):508-17. PubMed ID: 21080209
[TBL] [Abstract][Full Text] [Related]
9. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
Zhu WB; Zhao ZF; Zhou X
J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
[TBL] [Abstract][Full Text] [Related]
10. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
11. Activated hepatic stellate cells regulate MDSC migration through the SDF-1/CXCR4 axis in an orthotopic mouse model of hepatocellular carcinoma.
Xu Y; Fang F; Jiao H; Zheng X; Huang L; Yi X; Zhao W
Cancer Immunol Immunother; 2019 Dec; 68(12):1959-1969. PubMed ID: 31641797
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro.
Li JK; Yu L; Shen Y; Zhou LS; Wang YC; Zhang JH
World J Gastroenterol; 2008 Apr; 14(15):2308-13. PubMed ID: 18416455
[TBL] [Abstract][Full Text] [Related]
13. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy.
Chaudary N; Pintilie M; Jelveh S; Lindsay P; Hill RP; Milosevic M
Clin Cancer Res; 2017 Mar; 23(5):1242-1249. PubMed ID: 27697997
[No Abstract] [Full Text] [Related]
15. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
17. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
18. Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression.
Sorrentino C; Miele L; Porta A; Pinto A; Morello S
Oncotarget; 2016 Sep; 7(39):64274-64288. PubMed ID: 27590504
[TBL] [Abstract][Full Text] [Related]
19. The critical roles of tumor-initiating cells and the lymph node stromal microenvironment in human colorectal cancer extranodal metastasis using a unique humanized orthotopic mouse model.
Margolin DA; Myers T; Zhang X; Bertoni DM; Reuter BA; Obokhare I; Borgovan T; Grimes C; Green H; Driscoll T; Lee CG; Davis NK; Li L
FASEB J; 2015 Aug; 29(8):3571-81. PubMed ID: 25962655
[TBL] [Abstract][Full Text] [Related]
20. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
Daniel SK; Seo YD; Pillarisetty VG
Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
